What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

CRISPR Sequence Example for Gene Therapy: A Guide

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to CRISPR and Gene Therapy

What is CRISPR-Cas9?

CRISPR-Cas9 is an adaptive immune system originally discovered in Streptococcus pyogenes that has been repurposed as a programmable genome-editing tool. The system consists of two core components: the Cas9 endonuclease, a 160 kDa protein that cleaves double-stranded DNA, and a single-guide RNA (sgRNA), a synthetic fusion of the CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) that directs Cas9 to a specific genomic locus via Watson-Crick base pairing.

The Cas9 protein contains two nuclease domains—the HNH domain, which cleaves the strand complementary to the guide RNA, and the RuvC domain, which cleaves the non-complementary strand. When both domains are active, Cas9 generates a blunt double-strand break (DSB) three base pairs upstream of the protospacer adjacent motif (PAM). The PAM is a short, conserved sequence—for S. pyogenes Cas9, it is 5′-NGG-3′—that is essential for target recognition. Without a PAM immediately downstream of the target sequence, Cas9 will not bind or cleave.

The therapeutic promise of CRISPR-Cas9 lies in its programmability. By simply changing the 20-nucleotide spacer sequence of the sgRNA, researchers can redirect Cas9 to virtually any genomic locus that is followed by a PAM. This has opened the door to treating monogenic disorders by either disrupting a pathogenic gene, correcting a mutation, or modulating gene expression.

Gene Therapy: Concept and Challenges

Gene therapy aims to treat or prevent disease by altering the genetic material within a patient's cells. Traditional gene therapy relied on viral vectors to deliver a functional copy of a gene, but this approach has limitations: transgene expression can be silenced over time, random integration can disrupt tumor suppressor genes, and the therapeutic gene may be too large for the delivery vehicle.

CRISPR-based gene therapy offers a fundamentally different strategy. Rather than adding a new gene, CRISPR edits the existing genome at a precise location. This allows for three distinct therapeutic outcomes: gene knockout, where a pathogenic allele is disrupted; gene correction, where a mutation is repaired using a homologous template; and gene regulation, where CRISPR components are used to activate or repress transcription without cutting DNA.

The challenges of CRISPR gene therapy are substantial. Delivery must be efficient and cell-type-specific. Off-target editing must be minimized to avoid introducing new mutations. The immune system may recognize Cas9 as a foreign protein and mount a response. And for many diseases, the edited cells must engraft and persist for the patient's lifetime. Despite these hurdles, the field has advanced rapidly, with the first CRISPR-based therapy receiving regulatory approval in 2023.

Anatomy of a CRISPR Sequence for Gene Therapy

Guide RNA Design

The sgRNA is the specificity determinant of the CRISPR system. It is typically 100 nucleotides in length, consisting of a 20-nucleotide spacer at the 5′ end that is complementary to the target DNA sequence, followed by a scaffold region that binds Cas9. The spacer sequence must be exactly complementary to the target genomic locus, with the caveat that the target must be immediately followed by a PAM sequence.

For therapeutic applications, the sgRNA is expressed from a DNA template using either a U6 promoter (for polymerase III-driven transcription) or an H1 promoter. The U6 promoter requires the first nucleotide of the sgRNA to be a guanine for efficient transcription; therefore, if the target sequence does not naturally begin with G, an extra G is often added to the 5′ end of the spacer. This does not significantly affect targeting efficiency in most cases.

The design of a therapeutic sgRNA requires consideration of both on-target efficiency and off-target potential. The 20-nucleotide spacer should have a GC content between 40% and 80%, as extreme GC content can reduce binding efficiency or promote secondary structure formation. The seed region—the 8–12 nucleotides proximal to the PAM—is the most critical for target recognition; mismatches in this region are poorly tolerated, while mismatches in the distal region are more forgiving.

PAM Sequence and Target Selection

The PAM is a short sequence motif that is required for Cas9 binding. For S. pyogenes Cas9, the most commonly used variant, the PAM is 5′-NGG-3′. This means that every target site must have a guanine dinucleotide immediately downstream of the 20-nucleotide spacer. The PAM is not part of the sgRNA and is not cleaved by Cas9; it is recognized by the PAM-interacting domain of the Cas9 protein.

The requirement for an NGG PAM constrains target selection. On average, an NGG PAM occurs once every 8 base pairs in the human genome, which means that most genes contain multiple potential target sites. However, for therapeutic applications, the target site must be chosen not only for accessibility but also for functional relevance. For example, if the goal is to disrupt a dominant negative mutation, the target should be in the early coding region of the gene, where a frameshift will lead to nonsense-mediated decay of the mRNA. If the goal is to excise a specific exon, two sgRNAs must be designed flanking the exon, each with its own PAM.

Engineered Cas9 variants with altered PAM specificities have expanded the targeting repertoire. SpCas9-NG recognizes 5′-NG-3′, SpCas9-VQR recognizes 5′-NGA-3′, and SpCas9-SaCas9 recognizes 5′-NNGRRT-3′. These variants are useful when the optimal target site lacks a canonical NGG PAM.

Designing a CRISPR Sequence: Step-by-Step

Selecting the Target Gene

The first step in designing a CRISPR sequence for gene therapy is to identify the gene and the specific mutation or region to be targeted. For autosomal recessive disorders, the goal may be to correct the mutation in both alleles. For autosomal dominant disorders, the goal may be to disrupt the mutant allele while preserving the wild-type allele. For disorders caused by haploinsufficiency, the goal may be to upregulate the remaining functional allele.

Once the gene is selected, the genomic sequence must be obtained from a reference genome (e.g., GRCh38 for human). The exon-intron structure must be annotated, and the specific mutation must be located. For gene correction via homology-directed repair (HDR), the target site should be within 50 base pairs of the mutation, as HDR efficiency decreases with increasing distance from the DSB.

Designing the sgRNA

The sgRNA design process can be broken into the following steps:

Identify candidate PAM sites within the target region. For SpCas9, scan the sequence for 5′-NGG-3′ motifs. Each PAM defines a potential 20-nucleotide target immediately upstream.

Extract the 20-nucleotide spacer for each candidate. The spacer is the sequence immediately 5′ of the PAM. For example, if the genomic sequence is 5′-...ATGCGTACGTAGCTAGCTAGCNGG...-3′, the spacer is the 20 nucleotides before the NGG.

Check for the U6 transcription start requirement. If the spacer does not begin with G, add a G to the 5′ end. This creates a 21-nucleotide sgRNA, but the added G does not need to match the genomic sequence.

Score the sgRNA for on-target efficiency. Several algorithms, including sgRNA Scorer 2.0 and CRISPRscan, predict cleavage efficiency based on sequence features such as GC content, position-specific nucleotide preferences, and secondary structure. A score above 0.6 (on a 0–1 scale) is generally considered acceptable.

Screen for off-target sites. Use tools such as Cas-OFFinder or CRISPOR to search the genome for sequences with high similarity to the spacer. Mismatches in the seed region are particularly dangerous. Off-target sites with 1–2 mismatches in the seed region or 3–4 mismatches overall should be flagged.

Select the final sgRNA based on the highest on-target score and the lowest off-target risk.

Off-Target Considerations

Off-target editing is the most significant safety concern in CRISPR gene therapy. Cas9 can tolerate mismatches between the sgRNA and the genomic DNA, particularly in the distal region of the spacer. The seed region (positions 1–12 from the PAM) is more sensitive, but even a single mismatch in the seed region does not completely abolish cleavage.

To mitigate off-target effects, several strategies are employed. High-fidelity Cas9 variants, such as SpCas9-HF1 and eSpCas9(1.1), contain mutations that reduce non-specific DNA contacts, thereby decreasing off-target cleavage while maintaining on-target activity. Truncated sgRNAs (17–18 nucleotides) have also been shown to reduce off-target effects, though they may also reduce on-target efficiency.

For therapeutic applications, off-target analysis must be performed genome-wide. Methods such as GUIDE-seq, CIRCLE-seq, and DISCOVER-seq empirically identify off-target sites in the cell type of interest. These methods typically identify fewer than 10 off-target sites for a well-designed sgRNA, and the majority of these are in intergenic or intronic regions.

Example CRISPR Sequences for Gene Therapy

Sickle Cell Anemia: BCL11A Enhancer

Sickle cell disease is caused by a single nucleotide mutation in the β-globin gene (HBB), resulting in the substitution of valine for glutamic acid at position 6 of the β-globin protein. Rather than correcting the HBB mutation directly, the approved therapy Casgevy (exagamglogene autotemcel) uses CRISPR-Cas9 to disrupt a specific enhancer element in the BCL11A gene.

BCL11A is a transcription factor that represses fetal hemoglobin (HbF) expression in adult erythroid cells. By disrupting the erythroid-specific enhancer of BCL11A, HbF expression is reactivated, compensating for the defective β-globin. The target sequence for this approach is located in the BCL11A erythroid enhancer, within an intronic region of the gene.

The sgRNA used in Casgevy targets the sequence 5′-GCTGGGATTATGGGCCAGGG-3′ (spacer) followed by an NGG PAM. The exact genomic coordinates are in the second intron of BCL11A on chromosome 2. Disruption of this enhancer reduces BCL11A expression specifically in erythroid progenitors, leading to HbF levels of 20–30% of total hemoglobin, which is sufficient to prevent sickling.

This approach is an example of Gene Therapy for Sickle Cell Disease that does not require a DNA repair template. The DSB is repaired by non-homologous end joining (NHEJ), which introduces small insertions or deletions (indels) that disrupt the enhancer function.

Duchenne Muscular Dystrophy: Exon Skipping

Duchenne muscular dystrophy (DMD) is caused by frameshift or nonsense mutations in the dystrophin gene (DMD), the largest gene in the human genome at 2.4 Mb. The reading frame of the dystrophin protein is critical; mutations that disrupt the reading frame lead to complete loss of functional dystrophin, while in-frame deletions produce a truncated but partially functional protein, as seen in the milder Becker muscular dystrophy.

CRISPR-mediated exon skipping aims to convert an out-of-frame mutation into an in-frame deletion by excising one or more exons. For example, in patients with mutations in exon 51, the goal is to delete exon 51 using two sgRNAs that flank the exon. This restores the reading frame, producing a shorter but functional dystrophin protein.

A typical pair of sgRNAs for exon 51 skipping targets sequences in intron 50 and intron 51. One sgRNA might target 5′-GTAAGTTGTAAGTTGTAAGT-3′ (spacer) in intron 50, while the other targets 5′-CACCTGTGTCATTCATTCAT-3′ (spacer) in intron 51. Each sgRNA requires its own NGG PAM immediately downstream. The two DSBs result in excision of the ~5 kb exon 51, and the intronic ends are rejoined by NHEJ.

This strategy is being pursued in clinical trials using AAV vectors to deliver the CRISPR components to muscle tissue. The efficiency of exon skipping in muscle is lower than in hematopoietic cells, and long-term expression of Cas9 in muscle raises immunogenicity concerns. Nevertheless, this approach demonstrates the versatility of CRISPR for treating large genes that cannot be delivered by conventional gene therapy.

Delivery Methods for CRISPR Components

Viral Vectors

The delivery of CRISPR components into target cells is a major challenge for gene therapy. The most commonly used viral vectors are adeno-associated viruses (AAV), lentiviruses, and adenoviruses.

AAV is the preferred vector for many in vivo applications due to its low immunogenicity, ability to transduce non-dividing cells, and long-term expression in post-mitotic tissues. However, AAV has a packaging capacity of approximately 4.7 kb, which is insufficient to accommodate both the Cas9 coding sequence (4.2 kb for SpCas9) and the sgRNA expression cassette in a single vector. This limitation is addressed by using a smaller Cas9 ortholog, such as Staphylococcus aureus Cas9 (SaCas9, 3.2 kb), or by splitting the Cas9 protein into two halves that are delivered in separate AAV vectors and reassemble via intein-mediated protein splicing.

Lentiviral vectors integrate into the host genome, providing stable expression of the CRISPR components. This is advantageous for ex vivo applications, where cells are edited in culture and then infused back into the patient. However, random integration carries a risk of insertional mutagenesis, and constitutive Cas9 expression increases the likelihood of off-target editing. For these reasons, lentiviral delivery is typically used with a self-inactivating design or with inducible promoters.

Non-Viral Methods

Non-viral delivery methods avoid the immunogenicity and insertional mutagenesis risks associated with viral vectors. Lipid nanoparticles (LNPs) are the most advanced non-viral platform, consisting of ionizable lipids that encapsulate mRNA encoding Cas9 and chemically modified sgRNA. LNPs are taken up by cells via endocytosis, and the ionizable lipid facilitates endosomal escape, releasing the mRNA and sgRNA into the cytoplasm. The mRNA is translated into Cas9 protein, which forms a complex with the sgRNA and enters the nucleus to edit the genome.

LNPs have been used successfully for ex vivo editing of hematopoietic stem cells in Casgevy, where the cells are electroporated with Cas9 protein and sgRNA rather than using LNPs. For in vivo delivery, LNPs accumulate primarily in the liver, making them suitable for treating liver-associated metabolic disorders but less effective for targeting other tissues.

Electroporation is the method of choice for ex vivo editing of hematopoietic stem cells and T cells. Cells are suspended in a buffer containing Cas9 protein and sgRNA, and a brief electrical pulse creates transient pores in the cell membrane, allowing the components to enter. Electroporation achieves high editing efficiencies (80–90%) in CD34+ hematopoietic stem cells but is associated with significant cell death (20–40%), which must be accounted for in the manufacturing process.

Mechanism of CRISPR-Mediated Gene Therapy

Non-Homologous End Joining (NHEJ)

When Cas9 induces a DSB, the cell repairs it primarily through NHEJ, which is active throughout the cell cycle and does not require a repair template. NHEJ directly ligates the two broken ends, but this process is error-prone. Small insertions or deletions (indels) are frequently introduced at the break site, often resulting in frameshift mutations that lead to premature stop codons and nonsense-mediated decay of the mRNA.

For gene therapy, NHEJ is harnessed for gene knockout. If the goal is to disrupt a pathogenic gene, the sgRNA is designed to target the early coding region, where a frameshift will truncate the protein. The efficiency of NHEJ-mediated knockout is typically 50–90% in cultured cells, depending on the target site and delivery method.

NHEJ can also be used for exon skipping, as described for DMD. When two DSBs are introduced flanking an exon, the intervening sequence is excised, and the intronic ends are rejoined. The efficiency of this approach depends on the distance between the two sgRNA target sites; excision efficiency decreases as the distance increases, with optimal distances of 1–5 kb.

Homology-Directed Repair (HDR)

HDR is a template-dependent repair pathway that is active primarily in the S and G2 phases of the cell cycle. To harness HDR for gene correction, a donor template must be provided alongside the CRISPR components. The donor template contains the desired sequence flanked by homology arms of 400–800 base pairs on each side.

The donor template can be delivered as a single-stranded oligodeoxynucleotide (ssODN) for small corrections (up to 200 bp) or as a double-stranded DNA plasmid or AAV vector for larger insertions. For ssODN, the homology arms are typically 40–60 nucleotides each, and the donor is designed to be complementary to the non-target strand to promote integration.

HDR efficiency is generally lower than NHEJ, typically 5–30% in dividing cells and near zero in non-dividing cells. To improve HDR efficiency, several strategies are employed: synchronizing cells in S phase using cell cycle inhibitors such as nocodazole or aphidicolin, using Cas9 variants fused to proteins that recruit HDR factors, or chemically modifying the donor template to resist exonuclease degradation.

For therapeutic applications, HDR is used when the goal is to correct a mutation rather than disrupt a gene. The first clinical trials using HDR for gene therapy are ongoing for diseases such as hemophilia B, where the factor IX gene is corrected in hepatocytes.

Evaluating CRISPR Efficacy and Safety

On-Target Editing Detection

The success of CRISPR editing must be verified at the DNA level. The most common method is Sanger sequencing of a PCR-amplified region spanning the target site. The presence of overlapping peaks downstream of the cut site indicates the presence of indels. For quantitative analysis, the T7 endonuclease I (T7E1) assay is used: PCR products are denatured and reannealed, and T7E1 cleaves heteroduplexes formed when wild-type and mutant strands hybridize. The fraction of cleaved DNA, measured by gel electrophoresis, provides an estimate of editing efficiency.

For precise quantification, next-generation sequencing (NGS) of the target region is the gold standard. NGS can resolve individual alleles and distinguish between different indel outcomes. Editing efficiency is reported as the percentage of reads containing indels, typically 50–90% for optimized systems.

For HDR, the detection of precise gene correction requires allele-specific PCR or digital droplet PCR. The presence of the corrected sequence can be confirmed by Sanger sequencing, but the proportion of corrected alleles must be quantified by NGS or by restriction enzyme digestion if the correction introduces or removes a restriction site.

Off-Target Effects and Mitigation

Off-target effects are identified using genome-wide methods. GUIDE-seq (genome-wide unbiased identification of DSBs evaluated by sequencing) tags DSBs with a short double-stranded oligonucleotide and identifies their genomic locations by NGS. CIRCLE-seq uses purified genomic DNA that is circularized and cleaved by Cas9 in vitro, followed by sequencing of the cleavage sites. DISCOVER-seq identifies off-target sites in cells by capturing the MRE11 protein that localizes to DSBs.

Once off-target sites are identified, their functional impact must be assessed. Off-target sites in coding regions, promoter regions, or known regulatory elements are of greatest concern. The frequency of off-target editing is typically 0.1–1% of the on-target frequency, but even low-frequency off-target events can be clinically significant if they disrupt a tumor suppressor gene.

Mitigation strategies include using high-fidelity Cas9 variants, truncated sgRNAs, and paired nickases (where two Cas9 nickases, each with one inactivated nuclease domain, generate staggered nicks that are repaired by HDR rather than NHEJ). For clinical applications, the final sgRNA is selected based on a comprehensive off-target analysis, and the manufacturing process includes rigorous quality control to ensure that the edited cell product has an acceptable off-target profile.

Clinical Applications and Case Studies

Approved CRISPR Therapies

The first CRISPR-based gene therapy to receive regulatory approval is Casgevy (exagamglogene autotemcel), approved by the UK Medicines and Healthcare products Regulatory Agency in November 2023 and by the US FDA in December 2023 for the treatment of sickle cell disease and transfusion-dependent β-thalassemia. Casgevy uses ex vivo editing of CD34+ hematopoietic stem cells with CRISPR-Cas9 to disrupt the BCL11A erythroid enhancer, as described in Section 4.1.

In clinical trials, Casgevy achieved transfusion independence in 28 of 29 patients with sickle cell disease and 28 of 32 patients with β-thalassemia at a median follow-up of 18 months. The edited cells engrafted successfully, and HbF levels increased to 20–30% of total hemoglobin. No serious adverse events related to off-target editing were reported.

The manufacturing process for Casgevy involves mobilizing CD34+ cells from the patient using plerixafor, editing the cells with Cas9 protein and sgRNA via electroporation, and infusing the edited cells back into the patient after myeloablative conditioning with busulfan. The entire process takes approximately 3–4 months from mobilization to infusion.

Ongoing Clinical Trials

Beyond Casgevy, numerous clinical trials are evaluating CRISPR-based therapies. For DMD, trials using AAV-delivered CRISPR for exon skipping are in early phases, with a focus on safety and biodistribution. For transthyretin amyloidosis, a therapy using LNP-delivered CRISPR to knock out the TTR gene in hepatocytes has shown promising results, with a single dose reducing serum TTR levels by more than 90% for over 12 months.

For inherited retinal diseases, subretinal injection of AAV-delivered CRISPR is being evaluated for the treatment of Leber congenital amaurosis caused by mutations in the CEP290 gene. The therapy targets a specific intronic mutation that creates a cryptic splice site; CRISPR is used to excise the mutation, restoring normal splicing.

For cancer immunotherapy, CRISPR is used to engineer chimeric antigen receptor (CAR) T cells with multiple gene knockouts. In one approach, the T cell receptor (TCR) and β2-microglobulin genes are disrupted to create universal donor cells that cannot cause graft-versus-host disease and are resistant to host rejection. These universal CAR-T cells are being evaluated in clinical trials for B-cell malignancies.

The field of CRISPR in Medicine is expanding rapidly, with new applications in CRISPR Knockout and CRISPR Knock strategies being developed for a wide range of genetic disorders.

Common Pitfalls and Practical Considerations

Design Errors

The most common mistake in CRISPR design is selecting a target site without verifying the PAM sequence. The PAM must be immediately 3′ of the spacer sequence; a PAM that is even one nucleotide away will not support Cas9 binding. Students should always check the genomic sequence for the NGG motif directly downstream of the proposed spacer.

A second common error is failing to account for the U6 promoter transcription start. If the sgRNA is expressed from a U6 promoter, the first transcribed nucleotide must be a G. If the target sequence does not begin with G, an extra G must be added. Failing to do so results in low or absent sgRNA expression.

A third error is choosing a target site in a region of high sequence homology. Repetitive elements, pseudogenes, and gene families can confound sgRNA design, as the sgRNA may target multiple loci. This is particularly problematic in genes such as the globin cluster, where high sequence similarity between genes can lead to unintended editing.

Experimental Pitfalls

Even with a well-designed sgRNA, experimental failures are common. One frequent issue is low editing efficiency due to poor delivery. For electroporation, the buffer composition, pulse voltage, and cell density must be optimized for each cell type. Typical conditions for CD34+ cells are 1–2 × 10⁵ cells in 20 µL of buffer, with a pulse of 140 V and 10 ms duration.

Another issue is the use of sgRNA with secondary structure. The sgRNA scaffold must fold correctly to bind Cas9; mutations in the scaffold can abolish activity. Chemically synthesized sgRNAs should be checked for purity by HPLC or PAGE, as truncated or degraded sgRNAs will reduce editing efficiency.

For HDR experiments, a common pitfall is using homology arms that are too short. For ssODN donors, homology arms of 40–60 nucleotides are recommended, but longer arms (up to 100 nucleotides) improve HDR efficiency. The donor should be designed to be complementary to the non-target strand, as this promotes integration of the correct sequence.

Finally, researchers often underestimate the importance of validating editing at the protein level. A frameshift mutation does not guarantee protein knockout; some truncated proteins retain partial function. Western blotting or flow cytometry should be used to confirm the absence of the target protein.

Frequently Asked Questions

What is a CRISPR sequence example for gene therapy?

A CRISPR sequence for gene therapy consists of a 20-nucleotide guide RNA spacer that is complementary to the target genomic DNA, followed by a PAM sequence (5′-NGG-3′ for SpCas9). For example, the sgRNA used in Casgevy for sickle cell disease targets the sequence 5′-GCTGGGATTATGGGCCAGGG-3′ in the BCL11A erythroid enhancer. The spacer is expressed as part of a longer sgRNA that includes a scaffold region for Cas9 binding.

How do you design a CRISPR guide RNA for gene therapy?

To design a guide RNA, you first select a target gene and identify a region to edit. You then scan the genomic sequence for NGG PAM sites and extract the 20-nucleotide sequence immediately upstream of each PAM. The candidate spacer is scored for on-target efficiency using algorithms such as CRISPOR, and off-target sites are identified using Cas-OFFinder. The final sgRNA is selected based on the highest on-target score and the lowest off-target risk.

What is the role of PAM in CRISPR gene therapy?

The PAM is a short sequence motif (5′-NGG-3′ for SpCas9) that is required for Cas9 to bind and cleave DNA. The PAM is recognized by the PAM-interacting domain of Cas9 and is essential for target discrimination. Without a PAM immediately downstream of the target sequence, Cas9 will not cleave. The PAM also determines which genomic sites can be targeted; the NGG requirement means that on average, one target site is available every 8 base pairs.

What are the delivery methods for CRISPR in gene therapy?

The main delivery methods are viral vectors (AAV, lentivirus, adenovirus) and non-viral methods (lipid nanoparticles, electroporation). AAV is used for in vivo delivery but has a limited packaging capacity. Lentivirus provides stable expression but carries a risk of insertional mutagenesis. Lipid nanoparticles are used for liver-targeted delivery, and electroporation is used for ex vivo editing of hematopoietic stem cells and T cells.

How does CRISPR correct a genetic mutation?

CRISPR corrects a genetic mutation by inducing a double-strand break at the target site, which is then repaired by one of two pathways. Non-homologous end joining (NHEJ) introduces small insertions or deletions that can disrupt a pathogenic gene. Homology-directed repair (HDR) uses a donor template to replace the mutated sequence with the correct sequence. HDR is less efficient than NHEJ and requires the cell to be in the S or G2 phase of the cell cycle.

What are off-target effects in CRISPR gene therapy?

Off-target effects are unintended edits at genomic sites that are similar but not identical to the target sequence. Cas9 can tolerate mismatches between the guide RNA and the genomic DNA, particularly in the distal region of the spacer. Off-target effects are identified using genome-wide methods such as GUIDE-seq and CIRCLE-seq. They are mitigated by using high-fidelity Cas9 variants, truncated guide RNAs, and careful sgRNA design.

What is the first CRISPR gene therapy approved?

The first CRISPR gene therapy approved is Casgevy (exagamglogene autotemcel), which received regulatory approval in the UK in November 2023 and in the US in December 2023. Casgevy is used to treat sickle cell disease and transfusion-dependent β-thalassemia by editing CD34+ hematopoietic stem cells to disrupt the BCL11A erythroid enhancer, reactivating fetal hemoglobin expression.

Key Takeaways

CRISPR-Cas9 is a programmable genome-editing tool consisting of a Cas9 endonuclease and a single-guide RNA that directs cleavage to a specific genomic locus.
The PAM sequence (5′-NGG-3′ for SpCas9) is essential for target recognition and must be immediately downstream of the 20-nucleotide guide RNA spacer.
Designing a CRISPR sequence for gene therapy requires selecting a target gene, identifying PAM sites, scoring sgRNA efficiency, and screening for off-target effects.
The two main repair pathways are NHEJ, which introduces indels for gene knockout, and HDR, which uses a donor template for precise gene correction.
Delivery methods include AAV and lentiviral vectors for in vivo delivery, and lipid nanoparticles and electroporation for ex vivo editing.
The first approved CRISPR therapy, Casgevy, disrupts the BCL11A erythroid enhancer to reactivate fetal hemoglobin in sickle cell disease and β-thalassemia.
Off-target effects are a major safety concern and are mitigated by high-fidelity Cas9 variants, truncated sgRNAs, and comprehensive genome-wide off-target analysis.